Follow-The-Filings

Security · featured owners

IART Integra Lifesciences Hldgs

COM NEW Equity as of 2026 Q2 among managers we track

  • 2 exits

holders

sorted by value · long equity only · current book 2026 Q2 · exits show last held size · open a manager for their book

history
Robert Olstein - Olstein Capital Management exited 2026 Q1 last 2025 Q4 0.31% Exit −0.31 pp 123,000 $2M history
Lee Ainslie - Maverick Capital exited 2026 Q2 last 2026 Q1 0.01% Exit −0.01 pp 72,108 $679K history

0 current · 2 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.54B $1.61B $1.64B
Gross profit * $884.74M $882.06M $831.62M
Gross margin * 57.4% 54.8% 50.9%
Net income $67.74M -$6.94M -$516.47M
Net margin * 4.4% -0.4% -31.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.06B $1.08B $1.16B
Total non-current assets * $2.72B $2.96B $2.44B
Total assets $3.78B $4.04B $3.6B
Total current liabilities $306.98M $922.13M $455.98M
Total non-current liabilities * $1.89B $1.57B $2.1B
Total equity $1.59B $1.55B $1.04B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $139.96M $129.38M $50.38M
Cash from investing -$94.18M -$390.81M -$108.06M
Cash from financing -$229.92M $237.86M $28.34M
Net change in cash -$180.26M -$30.03M -$11.33M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders